Section 1 Short title
This Act may be cited as the “United States Anti-Doping Agency Reauthorization Act”.
United States Anti-Doping Agency Reauthorization Act
A BILL
To reauthorize the United States Anti-Doping Agency, and for other purposes.
Sec. 2 Prohibit performance-enhancing methods
Section 701 of title VII of the Office of National Drug Control Policy Reauthorization Act of 2006 (21 U.S.C. 2001) is amended—
in subsection (a), by striking paragraph (4); and
in subsection (b)—
in paragraph (1), by inserting “and be recognized worldwide as the independent national anti-doping organization for the United States” after “Committee”;
in paragraph (2), by striking “, or performance-enhancing genetic modifications accomplished through gene-doping” and inserting “or prohibited performance-enhancing methods adopted by the Agency”;
in paragraph (3), by striking “, or performance-enhancing genetic modifications accomplished through gene-doping” and inserting “or prohibited performance-enhancing methods adopted by the Agency”;
in paragraph (4), by striking “and the prevention of use of performance-enhancing drugs, or performance-enhancing genetic modifications accomplished through gene-doping by United States amateur athletes; and” and inserting “, and the prevention of use by United States amateur athletes of performance-enhancing drugs or prohibited performance-enhancing methods adopted by the Agency.”; and
by striking paragraph (5).
Sec. 3 Authorization of appropriations
Section 703 of title VII of the Office of National Drug Control Policy Reauthorization Act of 2006 (21 U.S.C. 2003) is amended to read as follows:
“703. Authorization of appropriations
“There are authorized to be appropriated to the United States Anti-Doping Agency—
“(1) for fiscal year 2014, $11,300,000;
“(2) for fiscal year 2015, $11,700,000;
“(3) for fiscal year 2016, $12,300,000;
“(4) for fiscal year 2017, $12,900,000;
“(5) for fiscal year 2018, $13,500,000;
“(6) for fiscal year 2019, $14,100,000; and
“(7) for fiscal year 2020, $14,800,000.”